Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12020612 | 1.00 | OPRM1 (0.50) | OPRM1MAOAMAOBKDM1AMAP4K4 | |
| SCHEMBL25384668 | 0.81 | OPRM1 (0.54) | OPRM1MAOAMAOBKDM1AMAP4K4 | |
| SCHEMBL12020410 | 0.81 | OPRM1 (0.50) | OPRM1MAOAMAOBKDM1AMAP4K4 | |
| SCHEMBL25383049 | 0.81 | OPRM1 (0.50) | OPRM1MAOAMAOBKDM1AMAP4K4 | |
| SCHEMBL17985304 | 0.81 | MAOB (0.41) | MAOAMAOBCCR2PDE4APDE4B | |
| SCHEMBL1557855 | 0.81 | MAOB (0.41) | MAOAMAOBCCR2PDE4APDE4B | |
| SCHEMBL25382786 | 0.81 | WDR5 (0.35) | OPRM1OPRL1PDE4APDE4BPDE4C | |
| SCHEMBL8097375 | 0.81 | OPRL1 (0.46) | OPRM1MAOAMAOBOPRL1KMT2A | |
| SCHEMBL25382251 | 0.81 | OPRM1 (0.46) | OPRM1MAOAMAOBKDM1AMAP4K4 | |
| SCHEMBL14894636 | 0.81 | SLC6A3 (0.55) | OPRM1CCR2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388536-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4486444-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| CN-118871422-A | 3-Alkynyl carboxamides as AEP modulators | 豪夫迈·罗氏有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023165943-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| EP-1532122-B1 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME (US) | 2011-12-14 | — | — | EP | disclosed |
| US-7875642-B2 | 3-[1-(4-Chlorophenyl)-trans-3-fluorocyclobutyl]-4,5-dicyclopropyl-r-4H-1,2,4-triazole anhydrate; Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875642-B2 | 3-[1-(4-Chlorophenyl)-trans-3-fluorocyclobutyl]-4,5-dicyclopropyl-r-4H-1,2,4-triazole anhydrate; Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875642-B2 | 3-[1-(4-Chlorophenyl)-trans-3-fluorocyclobutyl]-4,5-dicyclopropyl-r-4H-1,2,4-triazole anhydrate; Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090186928-A1 | Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 | MERCK SHARP & DOHME LLC | 2009-07-23 | — | — | US | disclosed |
| US-20090186928-A1 | Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 | MERCK SHARP & DOHME LLC | 2009-07-23 | — | — | US | disclosed |
| WO-2005073200-A1 | NOVEL CRYSTALLINE FORMS OF AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | MERCK & CO., INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| EP-1532122-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | Merck & Co., Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME LLC | 2004-06-03 | — | — | US | disclosed |
| US-6730690-B2 | DELAYING THE ONSET OR REDUCING THE RISK OF DEVELOPING ATHEROSCLEROSIS IN A HUMAN PATIENT COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A COMPOUND OF INVENTION AND AN HMG-COA REDUCTASE INHIBITOR | MERCK & CO., INC. | 2004-05-04 | — | — | US | disclosed |
| US-20040048912-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK SHARP & DOHME LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003104208-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104207-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| EP-1353896-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF HYDROXYLATED CYCLOBUTYLALKYLAMINES | Sepracor Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20020115727-A1 | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines | SEPRACOR INC. | 2002-08-22 | — | — | US | disclosed |
| WO-2002046138-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF HYDROXYLATED CYCLOBUTYLALKYLAMINES | SEPRACOR INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048912-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | HSD11B1, HSD17B1, HSD11B2 | OPRM1 1495/4885MAOA 2126/4885MAOB 1944/4885 |
| US-20020115727-A1 | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines | HTR5A, TPH1, HTR1B | OPRM1 73/4885MAOA 19/4885MAOB 22/4885 |
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD11B2, HSD17B1 | OPRM1 1569/4885MAOA 2512/4885MAOB 1627/4885 |
| US-20250388536-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | CNR2, CNR1, FAAH2 | OPRM1 6/4885MAOA 1163/4885MAOB 1252/4885 |
| US-20090186928-A1 | Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD11B2 | OPRM1 3625/4885MAOA 1817/4885MAOB 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.